Six peptides.
Not FDA approval.
The October 30 notice resolves publication status, not drug approval. The HHS policy remains conditional, nonbinding and subject to change.
What the policy actually establishes ↗LESS NOISE. MORE CONTEXT.
Evidence-based peptide news for practitioners and business leaders
Peptide intelligence for the people
making decisions in practice.
SIGNAL → EVIDENCE → PRACTICEA changing field.A considered perspective.
Six peptides.
A plan is not
a product launch.
The company’s October 29 communication describes a planned Peptides+ specialty and contingent future access.
Read the Hims analysis ↗The field, in focus.
Explore the year ↗Thirty participants are not a treatment standard
An October systematic review found three small human studies and very-low-certainty evidence. The useful story is the design—not the promise.
Read the evidence ↗The whole offer matters more than a research-use footer
Two August FDA letters connect product claims, blends and injection-related tools. They are product-specific enforcement records, not verdicts about every peptide.
Read the evidence ↗Seven peptide families, fourteen substances, and a nonbinding process
The July PCAC briefing distinguishes free bases, acetate salts and proposed uses. FDA staff proposals are documented; committee vote outcomes remain unverified here.
Read the evidence ↗THE PROVIDER FILEA directory that
A directory that
shows its working.
377 source dossiers. Field-level evidence. Original references. No paid leaderboard, and no blanket verification badge.
Explore the provider file ↗RESEARCH DOSSIER / 001
MEDVi
- Pricing
- Partial
- Clinical relationship
- Source-labeled verified
- Current license audit
- Not established
A claim, its source and its limits—kept together.
Evidence has stages.
Our editorial approach ↗01 A signalWhat’s being claimed?→02 The sourceWhat does it establish?→03 The limitsWhat remains unknown?→04 The implicationWhy should a practice care?